A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil

BACKGROUND: Symptomatic benefits have been reported for 5-HT(6) receptor antagonists in Alzheimer’s disease (AD) trials. SAM-760 is a potent and selective 5-HT(6) receptor antagonist that has demonstrated central 5-HT(6) receptor saturation in humans at a dose of 30 mg. METHODS: This was a randomize...

Descripción completa

Detalles Bibliográficos
Autores principales: Fullerton, Terence, Binneman, Brendon, David, William, Delnomdedieu, Marielle, Kupiec, James, Lockwood, Peter, Mancuso, Jessica, Miceli, Jeffrey, Bell, Joanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887246/
https://www.ncbi.nlm.nih.gov/pubmed/29622037
http://dx.doi.org/10.1186/s13195-018-0368-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887246/
https://www.ncbi.nlm.nih.gov/pubmed/29622037
http://dx.doi.org/10.1186/s13195-018-0368-9

Ejemplares similares